filmov
tv
IDM’s Rinaldo discusses HIV wonder drugs and curing HIV in 1998 World AIDS Day interview
Показать описание
UPMC HEALTH NEWS – In the late 1990s, new and highly potent anti-HIV drugs emerged— including protease and reverse transcriptase inhibitors—which could for the first time control HIV infection. Pitt Public Health AIDS researcher Charles Rinaldo of the Department of Infectious Diseases and Microbiology and the late Bridget Murtagh of the Pittsburgh AIDS Task Force address transmission, drug resistance, and the radically prescient question of whether HIV could be cured in this 1998 World AIDS Day telecast.
-------------
In the late 1990s, new, highly potent anti-HIV drugs were hailed as wonder drugs. Protease inhibitors and non-nucleoside and nucleoside reverse transcriptase inhibitors were controlling HIV infection for the first time. Just a few years earlier, University of Pittsburgh investigators from the Multicenter AIDS Cohort Study showed that the amount of 'HIV load' in the blood was the paramount predictor of HIV disease progression.
Scientists were testing to show that the 'viral load' in people treated with these new drugs decreased to undetectable levels within weeks, while their CD4 T cell counts steadily rose over many months.
The news media was full of front page stories on how HIV infection had finally been blunted. HIV-infected people were hailing miraculous recoveries and the possibility of leading normal, healthy lives.
On Nov. 25, 1998, just before World AIDS Day, Ann Devlin of the WTAE news team interviewed Pitt Public Health AIDS researcher Charles Rinaldo of the Department of Infectious Diseases and Microbiology for a UPMC telecast on HIV infection. Joining the interview was Bridget Murtagh, a nurse at a local hospital who had acquired HIV via a needlestick injury.
You will learn from this short video how, even then, they directly addressed whether HIV could be cured. This radical concept was prescient. Indeed, curing HIV infection is now a top objective of the Division of AIDS of the National Institutes of Health.
Today, Rinaldo and colleagues at Pitt are working on several potential cures for HIV infection. Sadly, Murtagh died of AIDS-related complications several years after this interview. An award in her honor, The Bridget Murtagh Award, was established by the AIDS Clinical Trials Group sponsored by the NIH.
-------------
In the late 1990s, new, highly potent anti-HIV drugs were hailed as wonder drugs. Protease inhibitors and non-nucleoside and nucleoside reverse transcriptase inhibitors were controlling HIV infection for the first time. Just a few years earlier, University of Pittsburgh investigators from the Multicenter AIDS Cohort Study showed that the amount of 'HIV load' in the blood was the paramount predictor of HIV disease progression.
Scientists were testing to show that the 'viral load' in people treated with these new drugs decreased to undetectable levels within weeks, while their CD4 T cell counts steadily rose over many months.
The news media was full of front page stories on how HIV infection had finally been blunted. HIV-infected people were hailing miraculous recoveries and the possibility of leading normal, healthy lives.
On Nov. 25, 1998, just before World AIDS Day, Ann Devlin of the WTAE news team interviewed Pitt Public Health AIDS researcher Charles Rinaldo of the Department of Infectious Diseases and Microbiology for a UPMC telecast on HIV infection. Joining the interview was Bridget Murtagh, a nurse at a local hospital who had acquired HIV via a needlestick injury.
You will learn from this short video how, even then, they directly addressed whether HIV could be cured. This radical concept was prescient. Indeed, curing HIV infection is now a top objective of the Division of AIDS of the National Institutes of Health.
Today, Rinaldo and colleagues at Pitt are working on several potential cures for HIV infection. Sadly, Murtagh died of AIDS-related complications several years after this interview. An award in her honor, The Bridget Murtagh Award, was established by the AIDS Clinical Trials Group sponsored by the NIH.